Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options-Reference-Cited by-同舟云学术

Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options

Published:2015-12-10 Issue:1 Volume:113 Page:55-61
ISSN:0022-4790
Container-title:Journal of Surgical Oncology
language:en
Short-container-title:J. Surg. Oncol.

Author:

Ang Celina¹,Miura John T.²,Gamblin T. Clark²,He Ruth³,Xiu Joanne⁴,Millis Sherri Z.⁴,Gatalica Zoran⁴,Reddy Sandeep K.⁴,Yee Nelson S.⁵,Abou-Alfa Ghassan K.⁶⁷

Affiliation:

1. Department of Medicine, Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York; New York

2. Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee; Wisconsin

3. Department of Medicine, Hematology/Oncology, Georgetown University Medical Center; Washington, DC

4. Caris Life Sciences, Phoenix; Arizona

5. Department of Medicine, Hematology/Oncology, Penn State Hershey Cancer Institute, Hershey; Pennsylvania

6. Memorial Sloan Kettering Cancer Center, New York; New York

7. Department of Medicine, Hematology/Oncology, Weill Cornell Medical College, New York; New York

Publisher

Wiley

Subject

Oncology,General Medicine,Surgery

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jso.24086/fullpdf

Reference43 articles.

1. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

2. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind placebo-controlled trial;Cheng;Lancet Oncol,2009

3. SEARCH: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma;Zhu;J Clin Oncol,2015

4. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: The EVOLVE-1 randomized clinical trial;Zhu;JAMA,2014

5. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study;Johnson;J Clin Oncol,2013

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future;Journal of Clinical and Translational Hepatology;2024-02-28

2. SPARC: a potential target for functional nanomaterials and drugs;Frontiers in Molecular Biosciences;2023-07-28

3. Inhibition of CDK9 exhibits anticancer activity in hepatocellular carcinoma cells via targeting ribonucleotide reductase;Toxicology and Applied Pharmacology;2023-07

4. The Treatment Landscape of Advanced Hepatocellular Carcinoma;Current Oncology Reports;2022-03-26

5. Immunotherapy Updates in Advanced Hepatocellular Carcinoma;Cancers;2021-04-30